Associated Papers
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.
Krook MA et al.
Cold Spring Harbor Molecular Case Studies, 2019
31371345 (PubMed )
Supplement: supp_mcs.a004002_Supplemental_S1.xlsx › Right_kidney_lymph_node
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › Patient_3_primary_1
Select a paper to view details